TY - JOUR T1 - UV-C Tower for point-of-care Decontamination of filtering facepiece respirators JF - medRxiv DO - 10.1101/2020.06.17.20133777 SP - 2020.06.17.20133777 AU - Badar J. Kayani AU - Davis T. Weaver AU - Vishvaan Gopalakrishnan AU - Eshan S. King AU - Emily Dolson AU - Nikhil Krishnan AU - Julia Pelesko AU - Michael J. Scott AU - Masahiro Hitomi AU - Jacob G. Scott AU - Ian Charnas Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/19/2020.06.17.20133777.abstract N2 - Filtering facepiece respirators (FFR) are critical for protecting essential personnel and limiting the spread of disease. Due to the current COVID-19 pandemic, FFR supplies are dwindling in many health systems, necessitating re-use of potentially contaminated FFR. Multiple decontamination solutions have been developed to meet this pressing need, including systems designed for bulk decontamination of FFR using vaprous hydrogen peroxide or UV-C radiation. However, the large scale on which these devices operate may not be logistically practical for small or rural health care settings or for ad hoc use at points-of-care. Here, we present the Synchronous UV Decontamination System (SUDS), a novel device for rapidly deployable, point-of-care decontamination using UV-C germicidal irradiation. We designed a compact, easy-to-use device capable of delivering over 2 J cm−2 of UV-C radiation in one minute. This short decontamination time should enable care-providers to incorporate decontamination of FFR into a normal donning and doffing routine following patient encounters.Disclaimer This article does not represent the official recommendation of the Cleveland Clinic or Case Western Reserve University, nor has it yet been peer reviewed.License This work is licensed under a Creative Commons Attribution Non-Commercial Share-Alike Attribution 4.0 International License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to extend our special thanks to Miguel Zubizarreta, whose generous and timely gift made this and many other COVID rapid response projects possibleAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patient data was used in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code, data, and technical documents are available at https://github.com/TheoryDivision/SUDS. https://github.com/TheoryDivision/SUDS ER -